Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OraSure, Schering-Plough lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Compound W Freeze Off marketer OraSure has reached an agreement on principal terms to settle pending patent infringement litigation against Schering-Plough Healthcare Products, which markets the Dr. Scholl's Freeze Away wart-removal product, firm announces Nov. 14. Under terms of the settlement, Schering-Plough will receive a license to OraSure's patents in the U.S. OTC market, and OraSure will receive monetary compensation from past and future sales. The settlement is subject to completion and execution of a final agreement. OraSure filed the lawsuit in 2004. Recently, an arbitration panel found in favor of OraSure starting Prestige Brands' 2006 acquisition of Wartner wart-removal line breached a no-compete agreement between the firms (1"The Tan Sheet" Oct. 29, 2007), In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel